

Enzyme Inhibitory, Antioxidant And Antibacterial Potentials Of Synthetic Symmetrical And Unsymmetrical Thioureas

This article was published in the following Dove Press journal:
Drug Design, Development and Therapy

Sumaira Naz¹
Muhammad Zahoor¹
Muhammad Naveed Umar¹
Barkat Ali^{1,2}
Riaz Ullah³
Abdelaaty A Shahat^{3,4}
Hafiz Majid Mahmood⁵
Muhammad Umar
Khayam Sahibzada⁶

¹Department of Chemistry, University of Malakand Chakdara, Dir Lower, Kpk 18800, Pakistan; ²Department of Chemistry, GC University Faisalabad, Faisalabad, Punjab, Pakistan; ³Medicinal, Aromatic and Poisonous Plants Research Center (MAPRC), College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; ⁴Phytochemistry Department, National Research Centre, Giza, Egypt; ⁵Department of Pharmacology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; ⁶Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Kpk 25000, Pakistan

Correspondence: Muhammad Umar
Khayam Sahibzada
Department of Pharmacy, Sarhad
University of Science and Information
Technology, Peshawar, KPK 25000,
Pakistan
Email umar.sahibzada@gmail.com

Muhammad Zahoor
Department of Chemistry, University of
Malakand Chakdara, Dir Lower, Kpk
18800, Pakistan
Email mohammadzahoor@yahoo.com

Background: In this study, 2 symmetrical and 3 unsymmetrical thioureas were synthesized to evaluate their antioxidant, antibacterial, antidiabetic, and anticholinesterase potentials.

Methods: The symmetrical thioureas were synthesized in aqueous media in the presence of sunlight, using amines and CS₂ as starting material. The unsymmetrical thioureas were synthesized using amines as a nucleophile to attack the phenyl isothiocyanate (electrophile). The structures of synthesized compounds were confirmed through H¹ NMR. The antioxidant potential was determined using DPPH and ABTS assays. The inhibition of glucose-6-phosphatase, alpha amylase, and alpha glucosidase by synthesized compounds was used as an indication of antidiabetic potential. Anticholinesterase potential was determined from the inhibition of acetylcholinesterase and butyrylcholinesterase by the synthesized compounds.

Results: The highest inhibition of glucose-6-phosphatase was shown by compound V (03.12 mg of phosphate released). Alpha amylase was most potently inhibited by compound IV with IC₅₀ value of 62 µg/mL while alpha glucosidase by compound III with IC₅₀ value of 75 µg/mL. The enzymes, acetylcholinesterase, and butyrylcholinesterase were potently inhibited by compound III with IC₅₀ of 63 µg/mL and 80 µg/mL respectively. Against DPPH free radical, compound IV was more potent (IC₅₀ = 64 µg/mL) while ABTS was more potently scavenged by compound I with IC₅₀ of 66 µg/mL. The antibacterial spectrum of synthesized compounds was determined against Gram-positive bacteria (*Staphylococcus aureus*) and Gram-negative bacteria (*Agrobacterium tumefaction* and *Proteus vulgaris*). Compound I and compound II showed maximum activity against *A. tumefaction* with MIC values of 4.02 and 4.04 µg/mL respectively. Against *P. vulgaris*, compound V was more active (MIC = 8.94 µg/mL) while against *S. aureus*, compound IV was more potent with MIC of 4.03 µg/mL.

Conclusion: From the results, it was concluded that these compounds could be used as antibacterial, antioxidant, and antidiabetic agents. However, further in vivo studies are needed to determine the toxicological effect of these compounds in living bodies. The compounds also have potential to treat neurodegenerative diseases.

Keywords: picolylamine, symmetrical thioureas, enzyme inhibition, anti-diabetic, antioxidant, Alzheimer's disease, antibacterial

Introduction

Thioureas are an important class of compounds that are used as intermediates/precursors in synthesis of many synthetic drugs.^{1,2} A number of substituted derivatives of thioureas can be synthesized by simple condensation of different primary and secondary amines (aliphatic and/or aromatic) with iso-thiocyanate or its derivatives.³ They can also be prepared by reaction of carbon disulphide and

amines (with or without catalyst).⁴ N,N'-disubstituted thioureas, whether aliphatic, aromatic or heterocyclic can be used as building blocks in the synthesis of heterocyclic compounds (having a variety of applications in different fields). In organic synthesis, they played a very important role as catalysts in important organic reactions (Mannich and Biginelli reactions) and as chelating agents.⁵ The diverse applications of these compounds in industry, agriculture, and medicine made them unique. Due to the presence of substituted sites in their structures, they have been used in drug design and synthesis.⁶ Literature on thiourea derivatives shows that they possess biological activities like anti-bacterial,⁷ anti-fungal, anti-cancer, analgesic, and antimalarial.⁸⁻¹³ They have also been used as inhibitors of certain enzymes like acetylcholinesterase, butyrylcholinesterase, carbonic anhydrase etc.¹⁴⁻¹⁷

Oxidative stress, diabetes mellitus, neurodegenerative diseases, and antibacterial resistance are the burning issues of this era. Free radicals are continuously produced during normal metabolism and nearly 1/4th of the inhaled oxygen is converted into free radicals, which have deteriorating effects on biologically important molecules like protein and DNA. Although human bodies are equipped with efficient systems to cope with these free radicals, for the last two decades, humans' dependence on synthetically processed food has complicated the issue and the amount of free radicals now produced is high as compared to the body's free radical scavenging capacities. Therefore, there is a need for certain potent compounds to be taken additionally, to help the body in scavenging the free radicals. As mentioned earlier, thioureas have two substitution sites that could be useful in such type of research.¹⁸⁻²¹

In neurodegenerative diseases, there is maximum hydrolysis of acetylcholine, the substance responsible for the transmission of nerve impulses at synaptic gaps between the two nerves. A practical approach applied to relieve the symptoms of neurodegenerative diseases is the use of inhibitors of acetylcholinesterase and butyrylcholinesterase (the enzymes responsible for hydrolyses of neurotransmitter acetylcholine).²² An example of neurodegenerative disease is Alzheimer's disease (AD) where an uncontrolled hydrolysis of the mentioned neurotransmitter occurs, rendering the neurotransmission difficult or almost impossible. If acetylcholinesterase is inhibited, the hydrolysis of acetylcholine can be controlled which can be helpful in the symptomatic relief of dementia or AD.¹⁸ Butyrylcholinesterase normally has a less significant role in hydrolysis of acetylcholine, but in the diseased condition, when acetylcholinesterase is

inhibited by medicines, its therapeutic importance increases as it could hydrolyze the available acetylcholine, minimizing the effect of the medicines, thus exaggerates the disease and its inhibition is then desired.^{19,23}

Diabetes mellitus is a metabolic disorder characterized by hyperglycemia, impairment of carbohydrate, lipid and protein metabolism, which is either due to insufficient secretion of insulin or insulin resistance. It is considered to be one of the chronic diseases after cancer and cardiovascular diseases. Among the different strategies used to control hyperglycemia, inhibition of the key enzymes of glucose metabolism like alpha amylase, alpha glucosidase and glucose-6-phosphatase is considered to be the most effective strategy.²⁰ α -Amylase cleaves polysaccharides at α -1,4 glycosidic linkages and the products (oligo and disaccharides) are further hydrolyzed to free glucose by intestinal α -glucosidase. Controlling/lowering activity of these two enzymes slows down the digestion of carbohydrates, absorption of glucose hence lowering the overall blood glucose level.^{24,25} Glucose-6-phosphatase catalyses the last step of both glycogenolysis (breakdown of glycogen) and gluconeogenesis (synthesis of glucose from non-carbohydrate sources) pathways, as a result glucose level is maintained during fasting condition. Inhibition of this enzyme is also considered to be a good therapeutic target in disorders of carbohydrate metabolism and would be helpful in minimizing the severity of fasting hyperglycemia occurring in diabetic patients.²⁶

Keeping in mind the therapeutic uses of thioureas, an attempt was made to synthesize novel symmetric and unsymmetric derivatives of thiourea and use them as remedy for oxidative stress, diabetes mellitus, and neurodegenerative disorders. The synthesized derivatives were also evaluated for their antibacterial potential against Gram positive and Gram negative bacterial strains.

Experimental Materials

All the chemicals, reagents, and solvents used were of analytical grade and were used without any further purification. They were purchased from Sigma Aldrich Co, St Louis, MO, USA. The reaction progress was monitored using thin layer chromatography (TLC). The structures of synthesized compounds were confirmed by ¹H-NMR in CDCl₃ using NMR-Bruker apparatus.

Methods

Cinchona alkaloids are a group of naturally occurring compounds with promising biological activities due to the presence of primary and tertiary nitrogens in their structures. Keeping in mind the importance of these alkaloids, the simplest commercially available analog 2-picolyl amine was taken and a simpler symmetrical thiourea presented as compound **II** was synthesized using CS₂ (1 equiv) in water and in the presence of sunlight. After confirmation that 2-picolyl amine has the capability of forming thiourea, the starting material 2-picolyl amine was derivatized to dibenzyl picolyl amine (Precursor **P**). Compound **I** and **III** were then synthesized using dibenzyl picolyl amine as starting material by two different methods described in the following section. Compound **IV** was prepared from 2,4-dimethyl aniline and phenyl isothiocyanate. Phenyl isothiocyanate is a commercially available compound, while 2,4-dimethyl aniline was prepared from 2, 4-dimethyl nitrobenzene by reduction of nitro group into amines by heterogenous catalyst under high pressure in the presence of hydrogen. Compound **V** was prepared from phenyl isothiocyanate and 2-fluoro aniline. The 2-fluoro aniline was prepared by reduction of the nitro group as described previously.

Preparation Of Dibenzyl Picolyl Amine (P)

The precursor dibenzyl picolyl amine was synthesized starting from acetylpyridine as more readily available starting material (Figure 1). The sodium hydride (NaH) was used to abstract proton from acetyl pyridine to make enolate which then attack on benzyl bromide (added drop-wise). As a result, first substitution takes place. With reaction progress under same condition, a second substitution takes place. The reaction product was then treated with hydroxyl amine hydrochloride. As a result, oxime




Figure 1 Chemical structure of 2-Benzyl-3-phenyl-1-(pyridin-2-yl)propan-1-amine (Precursor **P**).

was obtained which was then reduced into amine. The amine was purified further by column chromatography using ethyl acetate and hexane as solvent system.²⁷ The product was obtained as yellowish viscous oil with 68% yield.

Synthesis Of Symmetrical Thioureas (Compounds I And II)

Picolylamine/Picolylamine derivatives (1.0 mmol, 2.0 equiv) were mixed with carbon disulphide (0.5 mmol, 1.0 equiv) in 10 mL EtOH/H₂O (1:1) and placed in sunlight for 6–8 hrs. After 8 hrs, white precipitates were formed which were confirmed by NMR as symmetrical thioureas. The reaction mixture was kept at room temperature for 12 hrs until crystal formation.

Characterization Of Compound I

Brown crystals (yield 79%).

¹HNMR (300 MHz, CDCl₃-d) δ ppm: 4.5–4.7 (m, 8H), 5.2 (m, 2H), 5.4 (m, 2H), 6.8 (m, 4H), 6.9–7.1 (m, 8H), 7.2 (m, 8H), 7.5 (m, 2H), 7.7 (m, 2H), 8.1 (m, 2H), 8.5 (m, 2H), 8.9 (s, 2H). The chemical structure of compound **I** is given in Figure 2.

Characterization Of Compound II

Needle-like crystals (81% yield).

¹HNMR (300 MHz, CDCl₃-d) δ ppm: 3.2 (d, 4H), 6.4 (d, 4H), 6.5 (d, 2H), 7.3 (m, 4H), 8.2 (s, 2H). The structural formula of compound **II** has been presented in Figure 3.




Figure 2 1,3-bis(2-benzyl-3-phenyl-1-(pyridine-2-yl)propyl)thiourea (Compound **I**).




Figure 3 1,3-bis(1-(pyridin-2-yl)methyl)thiourea (Compound **II**).

Synthesis Of Unsymmetrical Thioureas (Compound III-V)

The required amines were mixed with phenyl iso-thiocyanate (both at the ratio of 1.0 equiv at a concentration of 1.0 mmol, 1.0) in 6 mL anhydrous acetone. The reaction mixture was then refluxed for 8–10 hrs at 52–56°C. Progress of the reaction was checked through TLC with EtOAc/n-hexane solution (3:7). The reaction mixture was then cooled using crushed ice. Precipitates formed were then filtered. Filtered precipitates were washed with water, dried and recrystallized using ethanol.

Characterization Of Compound III

Yellow crystals (yield 87%).

¹HNMR (300 MHz, CDCl₃-d) δ ppm: 2.32 (m, 1H), 2.59 (m, 2H), 2.77 (m, 2H), 3.08 (s, 1H), 7.04–7.28 (m, 15H), 7.37 (m, 2H), 7.65 (m, 2H), 7.82 (s, H, –NH), 8.47 (s, H, –NH). Compound III is presented in Figure 4.

Characterization Of Compound IV

Yield: 93%.

¹HNMR (300 MHz, CDCl₃-d) δ ppm 2.30 (s, 3H), 2.34 (s, 3H), 7.05 (d, 1H), 7.11 (d, 1H), 7.20 (s, 1H), 7.25 (m, 1H), 7.35–7.42 (m, 4H), 7.97 (s, 2H). Compound IV is presented in Figure 5.

Characterization Of Compound V

Yield: 96%.

¹HNMR (300 MHz, CDCl₃-d) δ ppm 7.0–7.49 (m, 9H), 7.8 (s, 1H, –NH), 7.9 (s, 1H, –NH). The chemical structure of compound V is given in Figure 6.

Anticholinesterase Assay

The acetylcholinesterase inhibitory potential of the synthesized compounds was examined using Ellman's assay.²⁸




Figure 4 1-(2-benzyl-3-phenyl-1-(pyridine-2-yl) propyl)-3-phenylthiourea (Compound III).




Figure 5 1-(2,4-dimethylphenyl)-3-phenylthiourea (Compound IV).

Acetylcholinesterase and butyryl cholinesterase hydrolyses their respective substrates acetylthiocholine iodide and butyrylthiocholine iodide. The resulting product reacts with 5-thio-2-nitrobenzoate anion formed from DTNB resulting in the formation of yellow color product. The color changes were measured spectrophotometrically which were then converted into enzyme activity and percent inhibition.

Briefly, 205 µL compound dilutions (1000–125 µL/mL) were mixed with 5 µL of AChE (0.03 U/mL)/BChE (0.01 U/mL) and 5 µL DTNB and incubated in water bath at 30°C for 15 min. Then, 5 µL acetyl choline iodide/butyryl choline iodide (substrate). As a result, formation of yellow color anion (5-Thio-2-nitro benzoate) took place. The color change was measured after 4 mins at 412 NM using a double beam spectrophotometer (Thermo electron-corporation; USA). A blank solution was considered as a control. Galanthamine was used as positive control. Activity and inhibition of the selective enzymes were calculated by following relations:

$$V = \Delta Abs / \Delta t \quad (1)$$

$$\% \text{ enzyme activity} = \frac{V}{V_{max}} \times 100 \quad (2)$$

$$\% \text{ enzyme inhibition} = 100 - \% \text{ enzyme activity} \quad (3)$$




Figure 6 1-(2-fluorophenyl)-3-phenylthiourea (Compound V).

Where, V is the inhibitor dependent rate of reaction while, V_{\max} is the inhibitor independent rate of reaction.

Antidiabetic Potential Of The Synthesized Compounds

The antidiabetic potential of synthesized compounds was checked by monitoring their inhibitory effects on three important enzymes of carbohydrate metabolism viz α amylase, α glucosidase, and glucose-6-phosphatase.

The stock solutions of the compounds were prepared in 10% DMSO and phosphate buffer (pH 6.9) having a concentration of 20 mM. Different dilutions (1000–125 mg/mL) were prepared for each compound. About 200 μ L of these dilutions was mixed with 200 μ L of porcine α -amylase (2 U/mL) and pre-incubated for 10 mins at 30°C. Added to the mixture, was 200 μ L of starch solution (1% w/v, made in 20 mM phosphate buffer, pH 6.9) and it was further incubated for 3 mins at 30°C. The reaction was stopped by adding 1 mL of 96 mM 3,5-dinitrosalicylic acid (DNS). Again, the reaction mixture was incubated for 10 mins in boiling water bath (85–90°C) and then cooled at room temperature. Acarbose was used as positive control. Absorbance was monitored at 540 nm and percent inhibition was calculated using the following equation:

$$\% \text{ inhibition} = \frac{\text{Control sample absorbance} - \text{Test sample absorbance}}{\text{Control absorbance}} \times 100 \quad (4)$$

The α -glucosidase inhibition was carried out by mixing 100 μ L of enzyme stock solution (0.5 unit/mL) with 600 μ L stock phosphate buffer (pH 6.9) and 50 μ L of each dilution prepared in the previous step and incubated at 37°C for 15 mins. To start the enzymatic reaction, 100 μ L *p*-nitro-phenyl- α -D-glucopyranoside (5 mM) was added to the mixture which reached completion after 15 mins incubation at 37°C. To stop the reaction, 400 μ L sodium carbonate (0.2 M) solution was added to the mixture. The absorbance of resulting mixture was measured at 405 nm. Percent inhibition of glucosidase was calculated using Formula 4. Acarbose was used as positive control and the same dilution was prepared by serial dilution.

The activity of the glucose-6-phosphatase was measured, which is based on the release of inorganic phosphate when the substrate glucose-6-phosphate is hydrolyzed by the enzyme. About 1 mL of 1 mM of the enzyme was taken, to which 1.5 mL tris (hydroxy methyl) amino methane buffer of pH 6.7 and 2.5 mL of 0.01 mM glucose-6-phosphate were added. The reaction mixture was incubated at 33°C for 1 hr. After the incubation, 1 mL 10% trichloroacetic acid was added to stop

the reaction, and inorganic phosphate released during the reaction was measured by method of Fiske and Subbarow.²⁹

Free Radical Scavenging Activities Of Synthesized Compounds

The free radical scavenging activities of synthesized compounds were determined following standard DPPH and ABTS protocols.¹⁰ DPPH stock solution was prepared by dissolving 20 mg of DPPH in 100 mL methanol. Blank (control) solution was prepared by taking 3 mL from the DPPH solution and its absorbance was adjusted to 0.75 at 515 nm. For the development of free radicals in stock solution, it was covered and kept in the dark for about 24 hrs. Stock solution (in 5 mL of methanol) of each compound was prepared and a series of dilutions (1000, 500, 250, 125, 62.5 μ g/mL) were then prepared from it, using dilution formula. About 2 mL from each dilution was mixed with 2 mL DPPH and allowed to react for 15 mins in the dark. The percent inhibition by DPPH was calculated with the following equation:

$$\% \text{ inhibition} = \frac{A - B}{A} \times 100 \quad (5)$$

Where; A = absorbance of pure DPPH in oxidized form.

B = absorbance of sample taken after 15 mins of reaction with DPPH.

Ascorbic acid (5 mg/5 mL) was taken as a standard and its different solutions (1000, 500, 250, 125 μ g/mL) were prepared.

The ABTS free radical scavenging was carried out using standard protocol of Re et al.³⁰ About 7 mM of ABTS and 2.45 mM of potassium per sulphate were dissolved, each in 100 mL of methanol and were then mixed together. To develop free radicals of ABTS, the reaction mixture was kept in the dark for 12 hrs. Absorbance of blank control (3 mL) was adjusted to 0.75 at 745 nm by diluting it with 50% methanol. About 300 μ L of each sample was taken, mixed with 3 mL of ABTS solution, and incubated for 15 mins at 25°C. Absorbance of the incubated mixture was measured at 745nm. The same procedure was done to prepare various dilutions of ascorbic acid (positive control). Percent free radical inhibition was calculated using Equation (5).

Anti-Bacterial Activities

The anti-bacterial activities of the synthesized compounds were determined against *Staphylococcus aureus*

(Gram-positive bacteria), *Agrobacterium tumefaction*, and *Proteus vulgaris* (Gram-negative bacteria) bacterial strain. Agar well diffusion method was used following the standard protocol.³¹

Statistical Analysis

All the experiments were performed in three replicates and the results have been presented as mean \pm SEM.

Results And Discussion

Effect Of Synthesized Compounds On Acetylcholinesterase And Butyrylcholinesterase

The effectiveness of the synthesized compounds as inhibitors of the selected cholinesterases was tested. The activities of both the enzymes were suppressed to a lesser or greater extent. The results are presented in [Tables 1](#) and [2](#) respectively, for acetylcholinesterase

Table 1 Effect Of The Compounds On The Activity Of Acetylcholinesterase Enzyme

Compound	Concentration ($\mu\text{g/mL}$)	%AChE Inhibition (mean \pm SEM)	IC ₅₀ $\mu\text{g/mL}$
I	1000	68.11 \pm 1.40	1002
	500	55.59 \pm 1.23	
	250	46.10 \pm 1.85	
	125	38.63 \pm 1.33	
II	1000	78.67 \pm 1.20	82
	500	72.16 \pm 2.01	
	250	59.21 \pm 1.21	
	125	52.55 \pm 1.73	
III	1000	84.31 \pm 1.12	63
	500	75.66 \pm 1.15	
	250	66.47 \pm 2.08	
	125	62.22 \pm 1.12	
IV	1000	64.02 \pm 1.70	503
	500	50.04 \pm 1.88	
	250	45.15 \pm 1.83	
	125	41.99 \pm 1.01	
V	1000	70.25 \pm 1.09	182
	500	68.15 \pm 1.25	
	250	56.34 \pm 2.14	
	125	51.78 \pm 1.72	
Galantamine	1000	93.22 \pm 0.81	40
	500	88.14 \pm 0.52	
	250	78.44 \pm 0.61	
	125	64.53 \pm 0.52	

Table 2 Effect Of The Compounds On The Activity Of Butyrylcholinesterase Enzyme

Compound	Concentration ($\mu\text{g/mL}$)	%BChE Inhibition (mean \pm SEM)	IC ₅₀ $\mu\text{g/mL}$
I	1000	57.81 \pm 0.54	200
	500	56.26 \pm 1.66	
	250	51.40 \pm 2.05	
	125	48.13 \pm 1.08	
II	1000	70.13 \pm 1.51	82
	500	62.31 \pm 2.11	
	250	59.15 \pm 1.60	
	125	65.71 \pm 1.28	
III	1000	68.55 \pm 1.07	80
	500	63.83 \pm 1.53	
	250	61.81 \pm 1.54	
	125	58.26 \pm 1.06	
IV	1000	76.14 \pm 1.90	150
	500	60.50 \pm 1.61	
	250	53.55 \pm 1.07	
	125	49.83 \pm 1.53	
V	1000	62.67 \pm 1.22	100
	500	59.07 \pm 1.76	
	250	55.09 \pm 1.04	
	125	53.07 \pm 0.48	
Galantamine	1000	92.30 \pm 0.74	55
	500	87.16 \pm 1.23	
	250	78.42 \pm 0.75	
	125	64.81 \pm 0.73	

and butyrylcholinesterase. As is clear from [Table 1](#), compound **III** was more potent against acetylcholinesterase with IC₅₀ value of 63 $\mu\text{g/mL}$, followed by compound **II** (IC₅₀ = 82 $\mu\text{g/mL}$). Compound **V** was moderately active with IC₅₀ value of 182 $\mu\text{g/mL}$ while compound **VI** and **I** were merely active (IC₅₀ = 503 and 1002 $\mu\text{g/mL}$ respectively).

The butyrylcholinesterase inhibitory activities of the synthesized compounds are presented in [Table 2](#). Almost the same trend observed for acetylcholinesterase was also observed here with little variations. Compound **III** was more active with IC₅₀ value of 80 $\mu\text{g/mL}$, followed by compound **II** with IC₅₀ = 82 $\mu\text{g/mL}$. Comparatively improved activities were observed for compound **I**, **IV**, and **V** with IC₅₀ values of 200, 150, and 100 $\mu\text{g/mL}$ respectively.

Based on the results obtained it can be concluded that compound **III** and **II** have some therapeutic values in the treatment of neurodegenerative diseases. However, in vivo studies regarding their toxicology are needed.

Effect Of Synthesized Compounds On The Activity Of Alpha Amylase

Alpha amylase is a key enzyme of carbohydrate metabolism that makes glucose available for the absorption in the small intestine from starch sources. Inhibition of this enzyme would be helpful in lessening the burden of blood glucose in diabetic patients. Table 3 shows the inhibitory potential of the compounds on alpha amylase. Compound IV with IC₅₀ value of 62 µg/mL was the most potent, followed by compound I (IC₅₀ = 84 µg/mL). Compound II, III, and V were also quite potent, but less than IV and I with IC₅₀ values of 135, 115, and 100 µg/mL respectively. All these compounds have inhibitory effects of alpha amylase which is clear from their IC₅₀ values.

Effect Of Synthesized Compounds On The Activity Of Alpha Glucosidase

Glucosidase is another important enzyme for carbohydrate metabolism and it helps in glucose release from starch

Table 3 Effect Of The Compounds On The Activity Of Alpha Amylase Enzyme

Compound	Concentration (µg/mL)	%Inhibition (mean ± SEM)	IC ₅₀ µg/mL
I	1000	70.29 ± 0.31	84
	500	68.08 ± 0.87	
	250	63.15 ± 1.41	
	125	60.23 ± 1.03	
II	1000	59.13 ± 0.15	135
	500	57.81 ± 2.25	
	250	56.04 ± 1.58	
	125	50.04 ± 0.10	
III	1000	65.82 ± 1.13	115
	500	62.49 ± 1.24	
	250	57.91 ± 0.43	
	125	50.07 ± 2.11	
IV	1000	80.12 ± 2.02	62
	500	79.18 ± 1.09	
	250	75.63 ± 0.63	
	125	69.04 ± 1.19	
V	1000	62.82 ± 1.13	100
	500	59.49 ± 1.24	
	250	55.91 ± 0.43	
	125	52.07 ± 2.11	
Acarbose	1000	88.09 ± 1.13	50
	500	72.98 ± 1.34	
	250	68.04 ± 1.88	
	125	58.13 ± 1.34	

Table 4 Effect Of The Compounds On Activity Of Enzyme Alpha Glucosidase

Compound	Concentration (µg/mL)	%Inhibition (mean ± SEM)	IC ₅₀ µg/mL
I	1000	51.13 ± 0.15	1000
	500	47.81 ± 2.25	
	250	46.04 ± 1.58	
	125	40.04 ± 0.10	
II	1000	72.02 ± 1.70	80
	500	71.04 ± 1.88	
	250	70.15 ± 1.83	
	125	69.99 ± 1.01	
III	1000	84.67 ± 1.20	75
	500	81.16 ± 2.01	
	250	79.21 ± 1.21	
	125	75.67 ± 1.20	
IV	1000	65.92 ± 0.23	180
	500	60.46 ± 0.083	
	250	55.88 ± 2.04	
	125	48.00 ± 1.34	
V	1000	57.18 ± 1.46	500
	500	52.14 ± 3.93	
	250	40.45 ± 1.59	
	125	32.49 ± 2.07	
Acarbose	1000	94.02 ± 1.23	60
	500	79.11 ± 2.12	
	250	68.14 ± 2.18	
	125	59.83 ± 2.04	

sources. In diabetic patients, its inhibition relieves the blood glucose burden. Compound III and II were more effective inhibitors of alpha glucosidase with IC₅₀ values of 75 and 80 µg/mL respectively. Compound IV appeared moderately active with IC₅₀ value of 180 µg/mL. Compound I and V were merely active with IC₅₀ values of 500 and 1000 µg/mL respectively (Table 4).

Effect Of Synthesized Compounds On The Activity Of Glucose-6-Phosphatase

Glucose-6-phosphatase is another important enzyme of carbohydrate metabolism that plays a very important role in glycogenolytic and gluconeogenic pathways. Its inhibition is needed in case of diabetes mellitus and enhancement of its activity is desired in patients suffering from glycogen storage disease. The inhibition of this enzyme is interpreted from the mg of inorganic phosphate released during the reaction. The smallest amount of phosphate released in a given reaction indicates high inhibition.

Table 5 Effect Of The Compounds On Activity Of Enzyme Glucose-6-Phosphatase

Compound	Concentration $\mu\text{g/mL}$	Total Activity*	Control
I	1000	21.20	72.0
	500	25.31	
	250	31.62	
	125	34.11	
II	1000	08.78	72.0
	500	10.07	
	250	13.10	
	125	15.60	
III	1000	24.23	72.0
	500	27.10	
	250	28.35	
	125	32.04	
IV	1000	10.10	72.0
	500	11.77	
	250	13.58	
	125	17.70	
V	1000	03.12	72.0
	500	04.16	
	250	05.21	
	125	05.66	

Note: *The activity has been expressed as mg of P released from the potassium salt of glucose-6-phosphate per hour (at 33°C, pH 6.7).

Compound **V** and **II** were the most potent inhibitors of this enzyme as the amount of phosphate released was comparatively less than that of other compounds (Table 5). Compound **I**, **III**, and **V** were also quite potent when compared to control experiments. As stated earlier, enhancers of this enzyme are also required in case of glycogen storage disease patients, however, even though all of these compounds were inhibitors of this enzyme, none of them exhibited the enhanced role.

Free Radical Scavenging Activities Of The Compounds

Free radicals are the chemically reactive substances with singlet electron. Free radicals are continuously produced in the human body and are promptly scavenged by the body's defense system. However, when their production increases, supplementation of antioxidants are needed from outside, otherwise they damage the biologically important molecules (DNA and protein). All these synthesized compounds showed scavenging activities against the commercially available free radicals DPPH and ABTS, which is clear

from Table 6. Compound **IV** was a more potent inhibitor of DPPH free radical ($\text{IC}_{50} = 64 \mu\text{g/mL}$) followed by compound **I** ($\text{IC}_{50} = 67 \mu\text{g/mL}$). Compound **V** and **III** were also quite effective in scavenging the DPPH radical and exhibited IC_{50} values of 70 and 79 $\mu\text{g/mL}$ respectively. The least effective compound was compound **II**.

A totally different inhibitory pattern was observed in case of ABTS free radical. Compound **I** was more potent with IC_{50} value of 66 $\mu\text{g/mL}$, followed by compound **III** and **V** ($\text{IC}_{50} = 80$ and 85 $\mu\text{g/mL}$ respectively). Compound **IV** was moderately effective while compound **II** was the least effective one.

Anti-Bacterial Activities Of The Compounds

The antibacterial spectrum of the synthesized compounds was determined against *A. tumefaction*, *P. vulgaris*, and *S. aureus*. The results have been presented in Table 7. Among the tested compounds, compound **I** was highly active against *A. tumefaction* with MIC value of 4.02 $\mu\text{g/mL}$ followed by compound **II** (MIC = 4.02 $\mu\text{g/mL}$). Against the same bacteria, compound **III**, **IV** and **V** were also quite effective with MIC values of 11.62, 13.49, and 11.59 $\mu\text{g/mL}$ respectively.

Against *P. vulgaris*, compound **V** was more effective followed by compound **I** (MIC = 8.94 and 9.76 $\mu\text{g/mL}$ respectively). The rest of the compounds were also quite effective against this bacterial strain.

The growth of *S. aureus* was more effectively inhibited by compound **IV** (MIC= 4.03 $\mu\text{g/mL}$). The rest of the compounds were moderately active. Comparatively, all these compounds exhibited good antibacterial actions against all the selected bacterial strains.

Conclusion

The wide applicability of thioureas in various fields, especially in the field of medicines, makes it quite practical to study biological activities of an already synthesized compound or to synthesize some more and determine their therapeutic significance, if any. In this study, five new thioureas were synthesized from chiral amines in the presence of sunlight (hence eco-friendly and economic procedure) which were then used as starting material in the synthesis of N-heterocyclic thiourea compounds. The compounds were tested for their antibacterial, antioxidant, anticholinesterase, and antidiabetic potentials. Glucose-6-phosphatase was potently inhibited by compound **V** and **II**, α -amylase by

Table 6 Estimation Of Free Radical Scavenging Potential Through DPPH And ABTS Assays

Compound	Concentration $\mu\text{g/mL}$	DPPH % I (mean \pm S.E.M)	DPPH IC_{50} $\mu\text{g/mL}$	ABTS % I (mean \pm S.E.M)	ABTS IC_{50} $\mu\text{g/mL}$
I	1000	86.67 \pm 1.20	67	81.67 \pm 1.20	66
	500	82.16 \pm 1.01		80.16 \pm 2.01	
	250	80.21 \pm 1.21		78.21 \pm 1.21	
	125	78.55 \pm 1.73		77.55 \pm 1.93	
II	1000	57.59 \pm 1.23	120	55.67 \pm 1.12	400
	500	54.10 \pm 1.85		52.07 \pm 1.16	
	250	52.63 \pm 1.33		49.09 \pm 1.04	
	125	50.02 \pm 1.99		47.07 \pm 0.46	
III	1000	67.45 \pm 0.095	79	69.11 \pm 0.234	80
	500	66.07 \pm 0.283		68.27 \pm 0.532	
	250	64.74 \pm 0.267		66.25 \pm 0.123	
	125	61.14 \pm 0.177		64.77 \pm 0.087	
IV	1000	79.15 \pm 1.23	64	78.15 \pm 1.21	100
	500	74.13 \pm 1.51		74.99 \pm 1.51	
	250	69.31 \pm 2.11		70.13 \pm 0.05	
	125	66.15 \pm 1.70		64.81 \pm 1.05	
V	1000	73.14 \pm 1.10	70	75.04 \pm 0.10	85
	500	71.50 \pm 1.61		73.18 \pm 1.46	
	250	70.55 \pm 1.27		71.14 \pm 1.90	
	125	68.83 \pm 1.53		69.45 \pm 1.29	
Ascorbic acid	1000	90.14 \pm 0.76	35	88.17 \pm 0.43	55
	500	85.11 \pm 1.64		85.45 \pm 1.36	
	250	76.13 \pm 1.45		70.14 \pm 1.16	
	125	67.40 \pm 1.18		55.30 \pm 1.75	

Table 7 Evaluation Of Antibacterial Potential Of The Synthesized Compounds

Samples	Bacterial Species						
	Conc. ($\mu\text{g/mL}$)	<i>Agrobacterium tumefaction</i>		<i>Proteus vulgaris</i>		<i>Staphylococcus aureus</i>	
		ZI (mm)	MIC $\mu\text{g/mL}$	ZI (mm)	MIC $\mu\text{g/mL}$	ZI (mm)	MIC $\mu\text{g/mL}$
Compound I	10	21	4.02	15	9.76	13	19.58
	20	24		22		16	
	30	26		24		18	
Compound II	10	21	4.04	12	12.22	12	14.83
	20	23		22		19	
	30	26		26		23	
Compound III	10	15	11.62	12	14.96	15	14.93
	20	20		16		16	
	30	26		22		19	
Compound IV	10	14	13.49	14	11.92	21	4.03
	20	18		18		23	
	30	23		23		26	
Compound V	10	15	11.59	16	8.94	12	24.11
	20	20		21		14	
	30	25		24		16	

Abbreviations: ZI, Zone of inhibition; MIC, Minimum inhibitory concentration.

compound **IV** and **I**, α -glucosidase by compound **III** and **II** while acetylcholinesterase and butyrylcholinesterase were inhibited by compound **III** and **II**. As free radical scavengers, compound **IV** was a more potent inhibitor of DPPH radical while compound **II** was the most effective against ABTS. Their antibacterial evaluation revealed that all these compounds were effective against *A. tumefaction*. Even though the in vitro experiments pointed out the good biological activities of these compounds, it is still not safe to assume that they are good therapeutic agents and further testing and in vivo experiments are needed to fully assess its pharmacological applicabilities.

Availability Of Data And Material

The data in the form of the thesis will be provided on demand.

Acknowledgments

The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding this work through research group no RG-1440-100.

Author Contributions

S.N. and M.Z. conceived and designed the experiments; M. N.U., B.A., R.U. and M.U.K.S. performed the experiments; M.Z., A.A.S and H.M.M. analyzed the data; M.Z., and M. U.K.S contributed reagents and materials. All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

- Bhanja C, Jena S. Rational synthesis design of a potent anti-diabetic therapeutic 'pioglitazone' using retrosynthetic analysis. *J Chem Pharm Res.* 2012;4(9):4323–4333.
- Kulshrestha AA. *Physicochemical Studies of Some Compounds*. Saurashtra University; 2009.
- Didwagh SS, Piste PB, Burungale AS, Nalawade AM. Synthesis and antimicrobial evaluation of novel 3-(4, 6-diphenyl-6H-1, 3-thiazin-2-yl)-2-(4-methoxyphenyl) thiazolidin-4-one derivatives. *J Appl Pharm Sci.* 2013;3(11):122–127.
- Alkherraz AM, Lusta ZI, Zubi AE. Synthesis and use of thiourea derivative (1-phenyl-3-benzoyl-2-thiourea) for extraction of cadmium ion. *Int J Chem Nucl Metall Mater Eng.* 2014;8:118–120.
- Shaik T, Chennamsetty S, Devineni S, et al. Catalyst-free green synthesis of urea and thiourea derivatives of tetramethylguanidine (TMG) and evaluation of biological activity. *Published Bulgarian Chem Comm.* 2014;46(4):724–730.
- Wermuth C, Aldous D, Raboisson P, Rognan D. Medicinal chemistry: definitions and objectives, drug activity phases, drug classification systems. In: *The Practice of Medicinal Chemistry*. Academic Press; 2015.
- Nagalakshmi G, Maity T, Maiti B. Synthesis, characterization and anti-HIV evaluation of some novel 2-[(substitutedphenyl/heteroaryl) imino]-3-phenyl-1, 3-thiazolidin-4-ones. *Synthesis.* 2013;5(5):2079–2089.
- Pattan S, Kedar M, Pattan J, et al. Synthesis and evaluation of some novel 2, 4-thiazolidinedione derivatives for antibacterial, antitubercular and antidiabetic activities. *Indian J Chem.* 2012;51B:1421–1425. doi:10.1094/PDIS-11-11-0999-PDN.
- Bielenica A, Stefańska J, Stepień K, et al. Synthesis, cytotoxicity and antimicrobial activity of thiourea derivatives incorporating 3-(trifluoromethyl) phenyl moiety. *Eur J Med Chem.* 2015;101:111–125. doi:10.1016/j.ejmech.2015.06.027
- Kulakov I, Nurkenov O, Akhmetova S, Seidakhmetova R, Zhambekov Z. Synthesis and antibacterial and antifungal activities of thiourea derivatives of the alkaloid anabasine. *Pharm Chem J.* 2011;45(1):15–18.
- Hosseinzadeh H, Nassiri-Asl M. Avicenna's (Ibn Sina) the canon of medicine and saffron (*Crocus sativus*): a review. *Phytother Res.* 2013;27(4):475–483. doi:10.1002/ptr.4784
- Kumar V, Chimni SS. Recent developments on thiourea based anticancer chemotherapeutics. *Anticancer Agents Med Chem.* 2015;15(2):163–175.
- Bharate SB, Thompson CM. Antimicrobial, antimalarial, and antileishmanial activities of mono- and bis-quaternary pyridinium compounds. *Chem Biol Drug Des.* 2010;76(6):546–551.
- Choi J, Jee J-G. Repositioning of thiourea-containing drugs as tyrosinase inhibitors. *Int J Mol Sci.* 2015;16(12):28534–28548. doi:10.3390/ijms161226114
- Suyoga Vardhan D, Shantharam C, Suhas R, Sridhara M, Channe Gowda D. Synthesis and urease inhibition studies of ureas and thioureas derived from amino acids conjugated heterocycle. *International Journal of Chemical and Pharmaceutical Sciences.* 2013;4(3):54–58.
- Imran S, Taha M, Ismail NH, Fayyaz S, Khan KM, Choudhary MI. Synthesis, biological evaluation, and docking studies of novel thiourea derivatives of bisindolylmethane as carbonic anhydrase II inhibitor. *Bioorg Chem.* 2015;62:83–93. doi:10.1016/j.bioorg.2015.08.001
- Antunes S, Corre J-P, Mikaty G, Douat C, Goossens PL, Guichard G. Effect of replacing main-chain ureas with thiourea and guanidinium surrogates on the bactericidal activity of membrane active oligoureia foldamers. *Bioorg Med Chem.* 2017;25(16):4245–4252.
- Bari WU, Zahoor M, Zeb A, et al. Anticholinesterase, antioxidant potentials, and molecular docking studies of isolated bioactive compounds from *Grewia optiva*. *Int J Food Prop.* 2019;22(1):1386–1396.
- Zahoor M, Zafar R, Rahman NU. Isolation and identification of phenolic antioxidants from *Pistacia integerrima* gall and their anticholine esterase activities. *Heliyon.* 2018;4(12):e01007. doi:10.1016/j.heliyon.2018.e01007
- Nazir N, Zahoor M, Nisar M, et al. Phytochemical analysis and antidiabetic potential of *Elaeagnus umbellata* (Thunb.) in streptozotocin-induced diabetic rats: pharmacological and computational approach. *BMC Complement Altern Med.* 2018;18(1):332. doi:10.1186/s12906-018-2317-3
- Zahoor M, Shafiq S, Ullah H, Sadiq A, Ullah F. Isolation of quercetin and mandelic acid from *Aesculus indica* fruit and their biological activities. *BMC Biochem.* 2018;19(1):5.
- Ovais M, Ayaz M, Khalil AT, et al. HPLC-DAD finger printing, antioxidant, cholinesterase, and α -glucosidase inhibitory potentials of a novel plant *Olex nana*. *BMC Complement Altern Med.* 2018;18(1):1. doi:10.1186/s12906-018-2317-3

23. Saeed A, Zaib S, Ashraf S, et al. Synthesis, cholinesterase inhibition and molecular modelling studies of coumarin linked thiourea derivatives. *Bioorg Chem.* **2015**;63:58–63. doi:10.1016/j.bioorg.2015.09.009
24. Zahoor M, Jan R, Naz S. Investigation of repressive and enhance effects of fruit extracts on the activity of glucose-6-phosphatase. *Pak J Phar Sci.* **2016**;29(6):1985–1991.
25. Gleason CA, Juul SE. Inborn Errors of Carbohydrate, Ammonia, Amino Acid, and Organic Acid Metabolism. In: J Lawrence Merritt II, Renata C Gallagher, editors. *Avery's Diseases of the Newborn (Tenth Edition)*. Elsevier; **2018**:230–252.
26. Lee M-W, Chanda D, Yang J, et al. Regulation of hepatic gluconeogenesis by an ER-bound transcription factor, CREBH. *Cell Metab.* **2010**;11(4):331–339. doi:10.1016/j.cmet.2010.02.016
27. Nugent TC, Umar MN, Bibi A. Picolylamine as an organocatalyst template for highly diastereo- and enantioselective aqueous aldol reactions. *Org Biomol Chem.* **2010**;8(18):4085–4089.
28. Peng L, Rong Z, Wang H, et al. A novel assay to determine acetylcholinesterase activity: the application potential for screening of drugs against Alzheimer's disease. *Biomed Chromatogr.* **2017**;31(10):e3971. doi:10.1002/bmc.3882
29. Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. *J Biol Chem.* **1925**;66(2):375–400.
30. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. *Free Radic Biol Med.* **1999**;26(9–10):1231–1237. doi:10.1016/s0891-5849(98)00315-3
31. Cheruiyot K, Olila D, Kateregga J. In-vitro antibacterial activity of selected medicinal plants from Longisa region of Bomet district, Kenya. *Afr Health Sci.* **2009**;9(2):S42–S46.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also

been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>